中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2011年
7期
1036-1038,后插1
,共4页
游洪波%陈安民%孙凯%王国宾%王茂朋%张国良
遊洪波%陳安民%孫凱%王國賓%王茂朋%張國良
유홍파%진안민%손개%왕국빈%왕무붕%장국량
前软骨干细胞%基因转染%骨基质%明胶
前軟骨榦細胞%基因轉染%骨基質%明膠
전연골간세포%기인전염%골기질%명효
Precartilainous stem cells%Gene transfectection%Bone matrix%Gelatin
目的 观察高效绿色荧光蛋白(EGFP)基因修饰前软骨干细胞(PSCs)与骨基质明胶(BMG)复合体的成软骨活性.方法 EGFP基因转染PSCs得到EGFP基因修饰PSCs.将其与BMG的复合体体外培养后植入裸鼠右后肢肌袋中,左后肢植入BMG作对照.定期取材测定移植物的重量、细胞数,观察GFP表达,免疫组织化学检测Ⅱ型胶原表达.结果 EGFP基因修饰PSCs体外培养6周仍有较强GFP表达.移植后1～6 周均有较强GFP表达,3～6周有较强Ⅱ 型胶原表达.移植后2～6周复合体平均重量分别为(0.71±0.07)、(1.35±0.32)、(1.76±0.48)、(1.96±0.54)、(1.89±0.13)g,均比对照组重(P<0.01);1～6周时复合体平均所含细胞总数分别为(40.0±2.1)×106、(67.0±5.6)×106、(139.0±11.2)×106、(169.0±2.9)×106、(173.0±13.5)×106、(169.0±6.9)×106个,均大于对照组(P<0.01).结论 EGFP基因修饰PSCs与BMG复合体能在异位形成软骨组织.
目的 觀察高效綠色熒光蛋白(EGFP)基因脩飾前軟骨榦細胞(PSCs)與骨基質明膠(BMG)複閤體的成軟骨活性.方法 EGFP基因轉染PSCs得到EGFP基因脩飾PSCs.將其與BMG的複閤體體外培養後植入裸鼠右後肢肌袋中,左後肢植入BMG作對照.定期取材測定移植物的重量、細胞數,觀察GFP錶達,免疫組織化學檢測Ⅱ型膠原錶達.結果 EGFP基因脩飾PSCs體外培養6週仍有較彊GFP錶達.移植後1～6 週均有較彊GFP錶達,3～6週有較彊Ⅱ 型膠原錶達.移植後2～6週複閤體平均重量分彆為(0.71±0.07)、(1.35±0.32)、(1.76±0.48)、(1.96±0.54)、(1.89±0.13)g,均比對照組重(P<0.01);1～6週時複閤體平均所含細胞總數分彆為(40.0±2.1)×106、(67.0±5.6)×106、(139.0±11.2)×106、(169.0±2.9)×106、(173.0±13.5)×106、(169.0±6.9)×106箇,均大于對照組(P<0.01).結論 EGFP基因脩飾PSCs與BMG複閤體能在異位形成軟骨組織.
목적 관찰고효록색형광단백(EGFP)기인수식전연골간세포(PSCs)여골기질명효(BMG)복합체적성연골활성.방법 EGFP기인전염PSCs득도EGFP기인수식PSCs.장기여BMG적복합체체외배양후식입라서우후지기대중,좌후지식입BMG작대조.정기취재측정이식물적중량、세포수,관찰GFP표체,면역조직화학검측Ⅱ형효원표체.결과 EGFP기인수식PSCs체외배양6주잉유교강GFP표체.이식후1～6 주균유교강GFP표체,3～6주유교강Ⅱ 형효원표체.이식후2～6주복합체평균중량분별위(0.71±0.07)、(1.35±0.32)、(1.76±0.48)、(1.96±0.54)、(1.89±0.13)g,균비대조조중(P<0.01);1～6주시복합체평균소함세포총수분별위(40.0±2.1)×106、(67.0±5.6)×106、(139.0±11.2)×106、(169.0±2.9)×106、(173.0±13.5)×106、(169.0±6.9)×106개,균대우대조조(P<0.01).결론 EGFP기인수식PSCs여BMG복합체능재이위형성연골조직.
Objective To evaluate the chondrogenesis potential of composite of enhanced green fluorescent protein (EGFP) gene-modified precartilaginous stem cells (PSCs) and bone matrix gelatin (BMG) ectopically. Methods PSCs were transfected with pEGFP by means of lipofectamine. The composite of EGFP gene-modified PSCs and BMG was cultured in vitro, then implanted into the right thigh of athymic mice, and BMG implanted into the left thigh as control group. The harvested implants were weighed, and the number of cells and the expression of GFP were examined. The expression of type Ⅱ collegen was detected by using immunohistochemistry. Results EGFP gene-modified PSCs had high expression of GFP in vitro 6 weeks after purification. The composite had high expression of GFP from 1 to 6 weeks after implantation, and high expression of type Ⅱ collagen from 3 to 6 weeks. The mass of the composite was (0.71±0.07), (1.35±0.32), (1.76±0.48), (1.96±0.54), (1.89±0.13) g from 2 to 6 weeks, respectively, which was significantly greater than that in control group (P<0.01). The total number of cells in the composite was (40.0±2.1)×106, (67.0±5.6)×106, (139.0±11.2)×106, (169.0±2.9)×106, (173.0±13.5)×106, (169.0±6.9)×106 from 1 to 6 weeks, respectively, which was significantly greater than that in control group (P<0.01). Conclusion The composite of EGFP gene-modified PSCs and BMG could generate ectopic cartilaginous tissue.
